Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,201–8,300 of 15,747
May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?
Junior, P. F. G.-B., & Kalil, J. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100532 · Cited by 7
Nazar, W., Romantowski, J., Nazar, G., Niedoszytko, M., Braun-Dullaeus, R. C., & Daniłowicz‐Szymanowicz, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-03428-3 · Cited by 7
“It occurred in less than 1% of the vaccinated cohort 2,3,23,24 .”
InfluentialLocal mRNA Delivery from Nanocomposites Made of Gelatin and Hydroxyapatite Nanoparticles
Andrée, L., Egberink, R. O., Heesakkers, R., Suurmond, C. E., Joziasse, L. S., Khalifeh, M., Wang, R., Yang, F., Brock, R. E., & Leeuwenburgh, S. C. G. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12721 · Cited by 9
Herzog, N. K., Vasireddy, H., Drenner, D. A., & Rose, J. P. (2022) · Journal of Behavioral Medicine · doi:10.1007/s10865-022-00321-6 · Cited by 9
Hussein, N. A., Ali, E. A. A., El-Hakim, A. E., Tabll, A. A., El-Shershaby, A., Salamony, A., Shaheen, M. N. F., Ali, I., Elshall, M., & Shahein, Y. E. (2022) · Human Antibodies · doi:10.3233/hab-220003 · Cited by 8
Lv, H., Tsang, O. T., So, R. T. Y., Wang, Y., Yuan, M., Liu, H., Yip, G. K., Teo, Q. W., Lin, Y., Liang, W., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149234 · Cited by 6
Nakashima, K., Ishida, M., Matsui, H., Yoshida, C., Nagai, T., Shiraga, M., Nakaoka, H., Otsuka, Y., Nakagama, Y., Kaku, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2140549 · Cited by 7
McGrath, J., Kenny, C., Nielsen, C. S., Domegan, L. M., Walsh, C., Rooney, P., Walsh, S., Conlon, N. P., Brady, G., Ibrahim, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1078022 · Cited by 8
Limsalakpetch, A., Kum-Arb, U., Yongvanitchit, K., Im‐Erbsin, R., Ubalee, R., Waters, N. C., Vesely, B. A., Muramatsu, H., Weissman, D., Tam, Y. K., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102645 · Cited by 11
Takeuchi, K., Yanagisawa, H., Kurosawa, Y., Iida, Y., Kawai, K., & Fujimaki, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264541 · Cited by 7
Piñana, J. L., García‐Sánz, R., Martino, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006326 · Cited by 7
Kertes, J., Gez, S. B., Saciuk, Y., Supino‐Rosin, L., Shamir-Stein, N., Mizrahi-Reuveni, M., & Zohar, A. E. (2021) · medRxiv · doi:10.1101/2021.09.01.21262957 · Cited by 7
Valerio, V., Rampakakis, E., Zanos, T. P., Levy, T. J., Shen, H. C., McDonald, E. G., Frenette, C. H., Bernatsky, S., Hudson, M., Ward, B. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10091514 · Cited by 7
Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review)
Lyubavina, N. A., Сальцев, С. Г., Викторович, М. Н., Валерьевна, Т. Л., Пластинина, С. С., Левановна, Ш. М., TULICHEV, A. A., Юрьевна, М. М., & Макарова, Е. В. (2021) · Современные технологии в медицине · doi:10.17691/stm2021.13.3.09 · Cited by 7
Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A
Jonsson‐Schmunk, K., Ghose, R., & Croyle, M. A. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1899818 · Cited by 8
Sugihara, K., Wakiya, R., Kameda, T., Shimada, H., Nakashima, S., Kato, M., Miyagi, T., Ushio, Y., Mizusaki, M., Mino, R., et al. (2022) · Medicine · doi:10.1097/md.0000000000031288 · Cited by 6
“Although the safety and efficacy of the BNT162b2 vaccine were proved in the general population in 1 study,[3] patients receiving immunosuppressive therapy were excluded from that trial.”
BackgroundVaccine-Associated Autoimmunity: From Clinical Signals to Immune Pathways
Peng, M., & Wang, Z. (2025) · Vaccines · doi:10.3390/vaccines13111112 · Cited by 10
“The rapid development and deployment of COVID-19 vaccines have been pivotal in controlling viral transmission and dramatically reducing severe disease, hospitalization, and mortality [2].”
Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies
Klegerman, M. E., Peng, T., Seferovich, I., Rahbar, M. H., Hessabi, M., Tahanan, A., Wanger, A. R., Grimes, C. Z., Ostrosky-Zeichner, L. L., Koster, K. J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311777 · Cited by 9
Kozak, A., Mikhaylov, G., Khodakivskyi, P. V., Goun, E. A., Turk, B., & Vasiljeva, O. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102464 · Cited by 7
Gordon, M. M. V., Mwananyanda, L. M., Gill, C. J., & McCarthy, K. A. (2021) · medRxiv · doi:10.1101/2021.08.18.21262248 · Cited by 6
Shaker, M. S., Phillips, E. J., Blumenthal, K. G., Abrams, E. M., Banerji, A., Oppenheimer, J. J., Leek, T. K. V., Mack, D. P., Wickner, P. G., Singer, A. G., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.04.015 · Cited by 7
Mask mandate and use efficacy for COVID-19 containment in US StatesPreprint
Guerra, D. D., & Guerra, D. J. (2021) · medRxiv · doi:10.1101/2021.05.18.21257385 · Cited by 6
Stäb, S., Pearce, N. M., Tronrud, D. E., Ginn, H. M., Fadda, E., Santoni, G., & Thorn, A. (2024) · Crystallography Reviews · doi:10.1080/0889311x.2024.2363756 · Cited by 7
“Nevertheless, the currently used vaccines, Pfizer-BioNTech’s ‘ BNT162b2 ’ and Mod-erna’s ‘ mRNA-1273 ’, both using a stabilized prefusion spike, show a > 90% efficacy against wild-type SARS-CoV-2 after the second vaccination and six month follow up [240–244].”
Riley, S., Haw, D., Walters, C. E., Wang, H., Eales, O. D., Ainslie, K. E. C., Atchison, C. J., Fronterrè, C., Diggle, P. J., Page, A. J., et al. (2021) · medRxiv · doi:10.1101/2021.05.13.21257144 · Cited by 7
“Evidence from the vaccination programme in Israel (two doses of the BNT162b2 mRNA vaccine [10]) suggests a 95% efficacy against infection [11].”
BackgroundAl‐Saadi, J., Waldén, M., Sandell, M., Sohlmér, J., Grankvist, R., Friberger, I., Andersson, A., Carlsten, M., Chien, K. R., Lundberg, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101225 · Cited by 10
Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities
Moyet, J., Helle, F., Bourdenet, G., Joseph, C., Gubler, B., Deschasse, G., Defouilloy, I., Slovenski, T., François, C., Liabeuf, S., et al. (2021) · The journal of nutrition health & aging · doi:10.1007/s12603-021-1713-4 · Cited by 8
“Multiple studies have proven the effectiveness of these new vaccines in preventing reinfection by SARS-CoV-2 when administered in two doses and, moreover, that a single dose should suffice for patients who have been infected and cured (9-11).”
Utilization of genetic information for medicines development and equitable benefit sharing
Matsuyama, K., Kurihara, C., Crawley, F. P., & Kerpel‐Fronius, S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1085864 · Cited by 10
“In the COVID-19 pandemic, immediate public disclosure of the genome sequence of the virus and intensive collaboration among researchers, governments, pharmaceutical companies, patients, and citizens enabled unprecedented rapid, successful vaccine development (Baden et al., 2020; Polack et al., 2020; Voysey et al., 202…”
BackgroundPUBLIC HEALTH SURVEILLANCE FOR ADVERSE EVENTS FOLLOWING COVID-19 VACCINATION IN AFRICAPreprint
Anjorin, A. A., Odetokun, I. A., Nyandwi, J. B., et al. (2022) · doi:10.14293/111.000/000024.v1 · Cited by 7
Xu, K., Li, J., Xu, L., Ge, X., Wang, K., Wang, J., Qiao, Z., Quan, Y., & Li, C. (2024) · Vaccines · doi:10.3390/vaccines12010060 · Cited by 7
“The results of S-specific IgG antibody subtypes showed that regardless of the addition of adjuvants, the level of IgG1 antibodies was the highest.”
BackgroundWang, Z., Fang, X., Han, T., et al. (2022) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2022.11.018 · Cited by 7
Corrêa, I. A., Faffe, D. S., Galliez, R. M., Gonçalves, C. C. A., Maia, R. A., da Silva, G. P., Moreira, F. R. R., Mariani, D., Campos, M. F., Leitão, I. D. C., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.912138 · Cited by 7
“effectiveness has decreased substantially (41,42).”
Nemeth, K. L., Yauney, E., Rock, J. M., Bievenue, R., Parker, M. M., & Styer, L. M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01336-22 · Cited by 6
“cle or joint pain, and headache, are similar to those reported in other studies and clinical trial data (12, 13, 18, 20, 23, 37, 40).”
BackgroundResultProntskus, V., Fresse, A., Yelehe‐Okouma, M., Facile, A., Pietri, T., Simon, C., Souder, C. L., Beurrier, M., & Gillet, P. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2866 · Cited by 7
Hashiba, K., Fukasaka, M., Okuma, C., Kobayashi-Ooka, Y., Kajiwara, K., Sugiyama, A., Mizuno, T., Shimomura, Y., Maeda, Y., Sasaki, J., et al. (2026) · Nano Letters · doi:10.1021/acs.nanolett.5c06525 · Cited by 10
Multi-objective computational optimization of human 5′ UTR sequences
Yamada, K., Suga, K., Abe, N., Hashimoto, K., Tsutsumi, S., Inagaki, M., Hashiya, F., Abe, H., & Hamada, M. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf225 · Cited by 10
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis
Proietti, F., Landi, D., Ponzano, M., et al. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06559-x · Cited by 7
“Pivotal and registration trials showed that COVID-19 vaccines prevent symptomatic disease, morbidities, and mortality Sars-Cov2-related [15].”
BackgroundCairoli, E., & Espinosa, G. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.05.008 · Cited by 16
Venkatakrishnan, A., Kumar, P. M., Silvert, E., Garcia-Rivera, E., Szenk, M., Suratekar, R., Lenehan, P. J., Lindemer, E., O’Horo, J. C., Williams, A. W., et al. (2021) · SSRN Electronic Journal · doi:10.1101/2021.04.01.21254798 · Cited by 8
Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
Kitamura, M., Takazono, T., Yamaguchi, K., Tomura, H., Yamamoto, K., Harada, T., Funakoshi, S., Mukae, H., & Nishino, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082090 · Cited by 6
“Introduction Effective mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as BNT162b2 (Pfizer) and m-RNA1273 (Moderna), are now widely available [1,2].”
Background(2021) · doi:10.1101/2021.11.14.21266309 · Cited by 7
“Novel vaccines based on mRNA and adenovirus-vector platforms [3; 4; 5, 6; 7; 8] and more traditional vaccines—as whole inactivated virus or protein subunit vaccines— [9; 10; 11; 12] have fulfilled the required efficacy threshold (≥ 50%) [2] and received emergency use authorizations; however, less than 5% of doses admi…”
BackgroundZhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.722178 · Cited by 9
Current status of vaccine immunotherapy for gastrointestinal cancers
Suzuki, N., Shindo, Y., Nakajima, M., Tsunedomi, R., & Nagano, H. (2023) · Surgery Today · doi:10.1007/s00595-023-02773-y · Cited by 9
“The recent worldwide use of COVID-19 mRNA vaccines has also demonstrated the safety of this approach and opened the door to cancer vaccines [83].”
Kikuchi-Fujimoto-like lymphadenopathy following COVID-19 vaccine: diagnosis and management
Betancur, V., Net, J., Chapman, J. R., et al. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-252030 · Cited by 7
Noor, R. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00719-x · Cited by 7
“, BNT162b2 mRNA Covid-19 vaccine and mRNA-1273 SARS-CoV-2 vaccine have been found to be effective (approximately 95%) from Phase III clinical trials as well as from the respondents’ survey (Noor 2021c; Polack et al. 2020; Baden et al. 2021; Heinz and Stiasny 2021).”
BackgroundNucleic Acid Delivery Nanotechnologies for In Vivo Cell Programming
Balcorta, H. V., Guerrero, V., Bisht, D., & Poon, W. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00886 · Cited by 9
Gedık, B., Erol, M. K., Süren, E., et al. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104500 · Cited by 7
Hodgson, D., Liu, Y., Carolan, L. A., Mahanty, S., Subbarao, K., Sullivan, S. G., Fox, A., & Kucharski, A. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1487066 · Cited by 7
Nucleic acid therapy in pediatric cancer
Li, Y., Huang, B., Xue, Z., Gao, Y., & Zhuo, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106441 · Cited by 8
Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study
Mimura, W., Ishiguro, C., Maeda, M., Murata, F., & Fukuda, H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2350091 · Cited by 7
COVID-19 Vaccine Effectiveness
Shader, R. I. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.016 · Cited by 8
Ward, T., Paton, R. S., Overton, C. E., Mellor, J., Aziz, N. I. B. A., Charlett, A., & Fyles, M. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106461 · Cited by 7
COVID-19 Vaccine Acceptance Behavior among Hispanics/Latinxs in Nevada: A Theory-Based Analysis
Nerida, T. M., Sharma, M., Labus, B., et al. (2023) · Healthcare · doi:10.3390/healthcare11050688 · Cited by 7
Chevet, B., Figueroa‐Parra, G., Yang, J. X., Hulshizer, C. A., Gunderson, T. M., Duong, S. Q., Putman, M., Barbour, K. E., Crowson, C. S., & Duarte‐García, A. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.220220 · Cited by 7
The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 InfectionPreprint
McDonald, J., Enguita, F. J., Taylor, D. M., Griffin, R. J., Priebe, W., Emmett, M. R., Sajadi, M. M., Harris, A. D., Clement, J., Dybas, J. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.23.441024 · Cited by 7
Lee, J., Shin, E., Kim, H., Song, W., Kwon, H., Kim, T., & Cho, Y. S. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.04.050 · Cited by 8
“The severity of these symptoms was classified from grades 1 to 4, in which grade 1 was mild (does not interfere with activity), grade 2 was moderate (interferes with activity), grade 3 was severe (prevents daily activity), and grade 4 was potentially life-threatening (requiring an emergency department visit or hospita…”
Kamanzi, A., Bido, A. T., Zhang, Y., Olsén, E., Stibbards-Lyle, M., Jasinski, M., Gu, Y., Wang, B. L., Venier-Karzis, M., Berti, R., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c17445 · Cited by 9
Maternal and perinatal outcomes of COVID-19 vaccination during pregnancy
Süt, H., Yıldız, G. A., Şeker, E., Umit, C., Koçar, M., & Koç, A. (2023) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2023.2022-9-10 · Cited by 8
“Despite the increased risk, pregnant women were not included in the initial vaccination schedule (4).”
BackgroundAcute ischemic stroke after first dose of inactivated COVID-19 vaccine: A case report
Elaidouni, G., Chetouani, Z., merbouh, C. B. M., Bkiyar, H., & Housni, B. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.02.082 · Cited by 9
“[1] Polack FP , Thomas SJ , Kitchin N , et al.”
Side effects of COVID-19 vaccinations in patients treated for breast cancer
Juhel, B. C., Brunelle, C. L., Bernstein, M. C., Smith, L. H., Jung, A. W., Ababneh, H., Hausman, E. K., Bucci, L. K., Bernstein, T., Naoum, G. E., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01050-z · Cited by 7
“The Pfizer study of the general population did not include LN swelling as a solicited event; however, it was reported as an adverse unsolicited event in 64 participants compared with 6 participants in the placebo group [6].”
BackgroundMethodResultInfluentialAgbayani, G., Akache, B., Renner, T. M., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202350620 · Cited by 7
“…schedules of COVID-19 mRNA vaccines were initially shown to be more than 90% effective against symptomatic disease in phase 3 clinical trials [2, 3], the emergence of immune-evasive variants of concern combined with the waning levels of vaccine-induced immunity has led to continued viral…”
BackgroundLett, M. J., Otte, F., Hauser, D., Schön, J., Kipfer, E. T., Hoffmann, D., Halwe, N. J., Breithaupt, A., Ulrich, L., Britzke, T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00992-z · Cited by 10
Sun, J., Wu, Y., Adjmi, M., Matthews, R. C., Kurian, A. A., Żak, M. M., Yoo, J., Mainkar, G., Lawless, H., Lu, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65344-4 · Cited by 7
Al‐Moubarak, E., Sharifi, M., & Hancox, J. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.645172 · Cited by 7
Kim, P. S., Schildhouse, R. J., Saint, S. K., Bradley, S., Chensue, S. W., Houchens, N., & Gupta, A. B. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.10.003 · Cited by 7
Acceptability of COVID-19 booster vaccine in malaysia: a cross-sectional study
Khoo, C. M. J., Dea, E. Z. Q., Law, L. Y., Wong, S. S. T., Ng, K. Y., & Bakhtiar, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-59195-0 · Cited by 9
Prolonged Diarrhea Following COVID-19 Vaccination: A Case Report and Literature Review
Akaishi, T., Takahashi, T., Sato, S., Jin, X., Masamune, A., & Ishii, T. (2022) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2022.j043 · Cited by 8
Narongkiatikhun, P., Noppakun, K., Chaiwarith, R., Winichakoon, P., Vongsanim, S., Suteeka, Y., Pongsuwan, K., Kusirisin, P., Wongsarikan, N., Fanhchaksai, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11040715 · Cited by 7
Modeling COVID-19 vaccine efficacy and coverage towards herd-immunity in the Basque Country, SpainPreprint
Stollenwerk, N., Mar, J., Van-Dierdonck, J. B., Ibarrondo, O., Estadilla, C. D. S., & Aguiar, M. (2021) · medRxiv · doi:10.1101/2021.07.12.21260390 · Cited by 7
Nakamura, S., Tanimura, Y., Nomura, R., Suzuki, H., Nishikawa, K., Kamegawa, A., Numoto, N., Tanaka, A., Kawabata, S., Sakaguchi, S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413465122 · Cited by 9
Design of a Multi-Valent SARS-CoV-2 Peptide Vaccine for Broad Immune Protection via Deep Learning
Feng, Z., Pang, X., Xu, Q., Gu, Z., Li, S., Zhu, L., & Li, H. (2025) · Engineering · doi:10.1016/j.eng.2025.04.025 · Cited by 7
Ghanaatpisheh, A., Safari, M., Haghshenas, H., Motamed‐Sanaye, A., Atefi, A. H., Kamangarpour, K., Bagherzadeh, M. A., Kamran-Jahromi, A., Darayesh, M., Kouhro, N., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1293920 · Cited by 9
“Two mRNA vaccines, BNT162b2 and mRNA1273, encode spike protein that is encapsulated in lipid nanoparticles, which promotes receptor recognition and viral entry into human cells (17, 29, 44).”
BackgroundHikichi, T., Sakamoto, M., Harada, M., Saito, M., Yamane, Y., Tokumura, K., & Nakamura, Y. (2022) · Journal of Human Genetics · doi:10.1038/s10038-022-01013-4 · Cited by 7
“Randomized trials demonstrated that Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 vaccines encoding the SARS-CoV-2 spike protein had ~95% protective ability against COVID-19 [1, 2].”
MethodAmmitzbøll, C. G., Thomsen, M. K., Andersen, J. B., Bartels, L. E., Hermansen, M. F., Johannsen, A. D., Mistegaard, C. E., Mikkelsen, S., Vils, S. R., Erikstrup, C., et al. (2022) · Modern Rheumatology · doi:10.1093/mr/roac069 · Cited by 8
“The phase 3 vaccine trials of the SARS-CoV-2 mRNA vaccines were encouraging but excluded most patients with rheumatic diseases (RDs) and patients treated with immunosuppressive therapy [1, 2].”
BackgroundZhang, M., Gong, Y., & Jiao, S. (2022) · Future Virology · doi:10.2217/fvl-2021-0100 · Cited by 7
“Multiple vaccines against SARS-CoV-2 have been approved by different countries for clinical use, for example, two mRNA vaccines (BNT162b2 from Pfizer-BioNTech, USA; mRNA-1273 from Moderna, USA) [56,57], three inactivated vaccines (BBIBP-CorV from Sinopharm, China; CoronaVac from Sinovac, China) [58–60], and four adeno…”
BackgroundLi, J., Hui, A., Zhang, X., Ge, L., Qiu, Y., Tang, R., Ye, H., Wang, X., Lin, M., Zhu, Z., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02206-1 · Cited by 8
“decision to advance BNT162b2 to the phase 2/3 trial [13], which has subsequently led to its global roll out.”
BackgroundSelf-citationZinc‐Coordinated Lipids: Facilitators for Enhanced mRNA Delivery Efficacy
Zhang, Y., Su, K., Shi, L., Wu, S., Yan, X., Zhang, Y., Wang, Z., Wang, W., Xu, T., & Liu, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202515406 · Cited by 8
mRNA COVID-19 Vaccine–Related Anaphylactoid Reaction and Coronary Thrombosis
Hinton, J., Gala, A. R. P. B. E., & Corbett, S. J. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.10.010 · Cited by 7
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
Bertram, S., Blazquez‐Navarro, A., Seidel, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10307-8 · Cited by 7
Shah, S. A., Robertson, C., Rudan, I., Murray, J., McCowan, C., Grange, Z., Buelo, A., Sullivan, C. B., Simpson, C. R., Ritchie, L. D., et al. (2022) · Journal of Global Health · doi:10.7189/jogh.12.05008 · Cited by 8
Dynamical intervention planning against COVID-19-like epidemics
Oliva, G., Schlueter, M., Munetomo, M., & Scala, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269830 · Cited by 7
Hirano, H., & Asada, H. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04889-2 · Cited by 10
Marziali, E., Pasqualetti, R., Bacci, G. M., et al. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2106248 · Cited by 7
“Data from COVID-19 vaccine clinical trials confirm that the BNT162b2 vaccine seems to induce both adaptive humoral and cellular immune responses in humans.(18,19) Our patient underwent successful corneal transplantation in May 2020 and his clinical picture remained stable with no signs of corneal graft rejection after…”
MethodIn Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds
Razak, M. R. M. A., Jelas, N. H. M., Muhammad, A., Padlan, N., Sa’at, M. N. F., Azizan, M. A., Rosli, S. N. Z., Ellan, K., Zainol, M., Thayan, R., et al. (2023) · Natural Product Communications · doi:10.1177/1934578x231188861 · Cited by 7
The efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines in patients with cancer
Şimşek, M., Yasin, A. I., Beşiroğlu, M., Topçu, A., İşleyen, Z. S., Şeker, M., & Türk, H. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27835 · Cited by 6
“We know from randomized controlled trials that vaccines against Covid‐19 are efficacious and infection in the general population is lower than in the unvaccinated population.(5,6) But for patients with a cancer diagnosis, there is limited data on Covid‐19 occurring after full dose vaccination and the efficacy of vacci…”
BackgroundMethodWesthölter, D., & Taube, C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab299 · Cited by 7
“Positive cases were detected 7 days (1), 14 days (10), 20 days (12) and 23 days (3) after the first vaccination (Figure 1).”
BackgroundTan, Z., Yang, C., Lin, P., Ramadan, S., Yang, W., Rashidi, Z., Lang, S., Shafieichaharberoud, F., Gao, J., Pan, X., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302755 · Cited by 8
Bellavite, P., Donzelli, A., & Isidoro, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237291 · Cited by 8
“…significant errors in the assessment of the risk/benefit ratio of vaccines, precisely in those categories characterized by greater fragility [1,140,141], as has been shown in a recent post-licensure study where the risk for all-causes of mortality (also accounting for underlying illnesses)…”
Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine
Meng, Z., Ma, D., Duan, S., Zhang, J., Yue, R., Li, X., Gao, Y., Li, X., Zeng, F., Xu, X., et al. (2022) · Vaccines · doi:10.3390/vaccines10060929 · Cited by 8
“In the early stages of the pandemic, these vaccines, including inactivated vaccines [31–33], mRNA vaccines [10,34,35], viral vector vaccines [9,36,37], protein subunit vaccines [11,38,39], and DNA vaccines [40,41], all provided satisfactory protection.”
BackgroundCOVID-19 in Patients with Hematologic Diseases
Casetti, I. C., Borsani, O., & Rumi, E. (2022) · Biomedicines · doi:10.3390/biomedicines10123069 · Cited by 9
A Case of Atypical Unilateral Optic Neuritis Following BNT162b2 mRNA COVID-19 Vaccination
Motegi, S., Kanda, T., & Takeuchi, M. (2022) · Vaccines · doi:10.3390/vaccines10101574 · Cited by 7
“BNT162b2 is a nucleoside-modified mRNA vaccine, which is translated into the SARS-CoV-2 spike protein by the host’s ribosomes, followed by antigen processing and presentation to local immune cells for subsequent neutralizing antibody production and T-cell-mediated immune response [27].”
BackgroundYamada, T., & Shi, S. (2022) · Applied Sciences · doi:10.3390/app12189236 · Cited by 11
Tran, A. P., Tassone, D., Nossent, J. C., & Ding, N. S. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002301 · Cited by 7
Allergische Reaktionen auf COVID-19-Impfstoffe – Evidenz und praxisorientiertes Vorgehen
Klimek, L., Eckrich, J., Hagemann, J., Casper, I., & Huppertz, J. (2021) · Der Internist · doi:10.1007/s00108-021-00959-5 · Cited by 8
Garofalo, E., Biamonte, F., Palmieri, C., Battaglia, A. M., Sacco, A., Biamonte, E., Neri, G., Antico, G. C., Mancuso, S., Foti, G., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281444 · Cited by 8
“The first cycle of vaccination induces a spike-specific humoral and cellular immune response that was shown to be efficient in 95% of naïve individuals [12].”
BackgroundLee, I., Lan, Y.-H., Wu, P., Wu, Y., Chen, Y.-H., Tseng, S.-C., Kuo, T.-J., Sun, C., Jan, J., Ma, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2149353 · Cited by 8
“at a rapid pace and are > 90% effective [31, 32].”
BackgroundLambìase, A., Sacchetti, M., Mallone, F., Tirassa, P., Greco, A., Angeloni, A., & Polimeni, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102430 · Cited by 7
“Introduction Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has shown high efficacy in preventing COVID-19 disease and improving the outcome of the infection [1].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.